MAP Kinase Signaling System
"MAP Kinase Signaling System" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An intracellular signaling system involving the MAP kinase cascades (three-membered protein kinase cascades). Various upstream activators, which act in response to extracellular stimuli, trigger the cascades by activating the first member of a cascade, MAP KINASE KINASE KINASES; (MAPKKKs). Activated MAPKKKs phosphorylate MITOGEN-ACTIVATED PROTEIN KINASE KINASES which in turn phosphorylate the MITOGEN-ACTIVATED PROTEIN KINASES; (MAPKs). The MAPKs then act on various downstream targets to affect gene expression. In mammals, there are several distinct MAP kinase pathways including the ERK (extracellular signal-regulated kinase) pathway, the SAPK/JNK (stress-activated protein kinase/c-jun kinase) pathway, and the p38 kinase pathway. There is some sharing of components among the pathways depending on which stimulus originates activation of the cascade.
Descriptor ID |
D020935
|
MeSH Number(s) |
G02.111.820.560 G03.493.560 G04.835.560
|
Concept/Terms |
ERK1-2 Pathway- ERK1-2 Pathway
- ERK1 2 Pathway
- ERK1-2 Pathways
- Pathway, ERK1-2
- Pathways, ERK1-2
- ERK1 and ERK2 Pathway
p38 Kinase Pathway- p38 Kinase Pathway
- Kinase Pathway, p38
- Kinase Pathways, p38
- Pathway, p38 Kinase
- Pathways, p38 Kinase
- p38 Kinase Pathways
- p38 Kinase Signaling Pathway
MAP Kinase Cascade- MAP Kinase Cascade
- Cascade, MAP Kinase
- Kinase Cascade, MAP
- MAP Kinase Cascades
- MAP Kinase Modules
- MAP Kinase Module
- Module, MAP Kinase
- MAP Kinase Signaling Cascades
MEK-ERK Pathway- MEK-ERK Pathway
- MEK ERK Pathway
- MEK-ERK Pathways
- Pathway, MEK-ERK
- Pathways, MEK-ERK
JNK Pathway- JNK Pathway
- JNK Pathways
- Pathway, JNK
- Pathways, JNK
- JNK Signaling Pathway
- JNK Signaling Pathways
- Pathway, JNK Signaling
- Pathways, JNK Signaling
- Signaling Pathway, JNK
- Signaling Pathways, JNK
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Signaling System".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Signaling System".
This graph shows the total number of publications written about "MAP Kinase Signaling System" by people in this website by year, and whether "MAP Kinase Signaling System" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 1 | 0 | 1 |
2000 | 5 | 5 | 10 |
2001 | 8 | 5 | 13 |
2002 | 12 | 7 | 19 |
2003 | 4 | 10 | 14 |
2004 | 5 | 13 | 18 |
2005 | 9 | 19 | 28 |
2006 | 7 | 16 | 23 |
2007 | 9 | 9 | 18 |
2008 | 8 | 13 | 21 |
2009 | 5 | 18 | 23 |
2010 | 4 | 14 | 18 |
2011 | 6 | 13 | 19 |
2012 | 7 | 17 | 24 |
2013 | 10 | 17 | 27 |
2014 | 11 | 24 | 35 |
2015 | 9 | 20 | 29 |
2016 | 9 | 10 | 19 |
2017 | 5 | 21 | 26 |
2018 | 12 | 15 | 27 |
2019 | 5 | 10 | 15 |
2020 | 5 | 12 | 17 |
2021 | 6 | 8 | 14 |
2022 | 2 | 5 | 7 |
2023 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Signaling System" by people in Profiles.
-
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer Res. 2023 12 15; 83(24):4161-4178.
-
The 8th International RASopathies Symposium: Expanding research and care practice through global collaboration and advocacy. Am J Med Genet A. 2024 Apr; 194(4):e63477.
-
Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. Mol Cancer Res. 2023 09 01; 21(9):867-880.
-
Restoring glomerular filtration rate by sulforaphane modulates ERK1/2/JNK/p38MAPK, IRF3/iNOS, Nrf2/HO-1 signaling pathways against folic acid-induced acute renal injury in rats. Int Immunopharmacol. 2023 Oct; 123:110777.
-
Discovery of IACS-52825, a Potent and Selective DLK Inhibitor for Treatment of Chemotherapy-Induced Peripheral Neuropathy. J Med Chem. 2023 07 27; 66(14):9954-9971.
-
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML. Leukemia. 2023 06; 37(6):1379-1383.
-
Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. J Biol Chem. 2022 08; 298(8):102226.
-
Role of p38 MAP kinase in cancer stem cells and metastasis. Oncogene. 2022 06; 41(23):3177-3185.
-
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022 04 28; 139(17):2601-2621.
-
Multiplexing the Quantitation of MAP Kinase Activities Using Differential Sensing. J Am Chem Soc. 2022 03 09; 144(9):4017-4025.